- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.06. | Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset | ||
| 26.06. | Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines | ||
| 26.06. | Alto misses primary efficacy endpoint in phase 2 depression trial | ||
| 26.06. | Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug | ||
| 26.06. | Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug | ||
| 25.06. | Minovia brings back SPAC with plans to skate into icy public market | ||
| 25.06. | Kymera suffers Sanofi setback but secures $750M Gilead deal | ||
| 25.06. | Arbutus regains China rights to potential functional hep B cure as part of strategic rethink | ||
| 25.06. | Biogen's Spinraza follow-up helps children with SMA who didn't benefit from Zolgensma | ||
| 25.06. | Bayer-owned BlueRock lays off 50 employees, shuts Cambridge research labs | ||
| 24.06. | Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data | ||
| 24.06. | Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential | ||
| 24.06. | MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b | ||
| 24.06. | Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates | ||
| 24.06. | Stuart sees dry eye disease drug fail phase 3 tear test, plans another study | ||
| 24.06. | Investors sweet on Nektar as phase 2b eczema success doubles share price | ||
| 24.06. | Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators | ||
| 23.06. | BrightGene tops Novo drug in diabetes ahead of Zepbound showdown | ||
| 23.06. | Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication | ||
| 23.06. | Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash | ||
| 23.06. | Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace | ||
| 23.06. | Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed | ||
| 23.06. | Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring | ||
| 23.06. | Otsuka pens $670M pact to point Harbour's preclinical T-cell engager to autoimmune disease | ||
| 23.06. | Novo's injectable amycretin yet to hit weight-loss plateau, suggesting Zepbound-beating potential |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .